Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of Tinlarebant in Healthy Adults
NCT04005807Phase 1Completed
- Sponsor
- Belite Bio, Inc
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tinlarebant in Stargardt disease (STGD) and age-related macular degeneration (AMD) (5 arms), sponsored by Belite Bio, Inc. Primary endpoints: Area under the plasma concentration versus time curve from time 0 to the last timepoint with quantifiable concentration, Area under the plasma concentration versus time curve from time 0 extrapolated to infinity and 14 more. Started Jul 2019; status: completed.
02
Drugs
tinlarebant
03
Conditions
Stargardt disease (STGD)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT04005807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04005807.